Clinical trial
Effect of Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced Stomach Cancer and Esophagogastric Junction. Phase II Clinical Trial.
NCT03549494 is registered in ClinicalTrials.gov with Catalysis SL as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced Stomach Cancer and Esophagogastric Junction. Phase II Clinical Trial.
- Lead sponsor
- Catalysis SL
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 25, 2018
- Completion date
- February 15, 2023
- Enrollment
- 45 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
digestive system disease, digestive system neoplasm, esophageal diseases, esophageal neoplasms, esophagogastric junction disorder, gastrointestinal disease, gastrointestinal neoplasms, head and neck neoplasms, stomach diseases, stomach neoplasm